Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021
HomeGlobal Health and BiodefenseAethlon Medical Announces Collaboration With Prostate On-Site Project

Aethlon Medical Announces Collaboration With Prostate On-Site Project

Today Aethlon Medical Inc. and its diagnostic subsidiary, Exosome Sciences, in collaboration with the Translational Genomics Research Institute and the Prostate On-Site Project announced that Aethlon,Translational Genomics Research (TGen) and Prostate On-Site Projeect (POP) will engage with participants for their studies of chronic traumatic encephalopathy (CTE) in living individuals during the 18th annual Jerry Colangelo Sports Legends Golf Classic in Phoenix.

Aethlon Medical reports study participants will include former athletes who may have experienced repeated head impacts, such as former NFL players, as well as controls, those who played sports such as baseball that usually do not have significant head impacts. All participants will provide samples for analysis of potential biomarkers of CTE.

Aethlon Medical aims to further validate TAUSOMETM, a CTE biomarker candidate, as an accurate and noninvasive biomarker for detection of CTE. Currently, CTE can only be diagnosed post-mortem.  Aethlon’s CTE studies are part of efforts to identify markers such as TAUSOMETM that will identify individuals currently living with CTE, as well as those at risk of developing CTE in their lifetimes.

TGen, an affiliate of City of Hope, will be looking for extracellular RNAs that may change as a result of head impact. These data will be incorporated with a series of studies on concussions and repetitive head impact exposure. Extracellular RNA changes are emerging as a new and sensitive tool to identify gene expression changes in the brain.

Aethlon Medical was part of one of the first CTE research programs funded by the National Institutes of Health (NIH) — The DETECT Study — which previously studied the TAUSOMETM biomarker. The study examined 78 former NFL players and a control group of 16 former non-contact sport athletes. The study showed that TAUSOMETM levels were significantly elevated in the NFL group as compared to the control group.  Notably, within the former NFL player group, higher TAUSOMETM plasma levels correlated with poorer performance on standardized tests of memory and psychomotor speed. These results were subsequently published in the Journal of Alzheimer’s Disease.

“The Jerry Colangelo tournament is an ideal location to engage with high-profile former athletes,” said Timothy C. Rodell, M.D., Interim Chief Executive Officer of Aethlon Medical. “Gene Felker, founder of POP and a prostate cancer survivor who was posthumously diagnosed with CTE, increased awareness among his fellow athletes of the importance of early detection of diseases such as prostate cancer and CTE. His daughter, Marla Felker Zimmerman, is carrying out his mission at the Jerry Colangelo Sports Legend Classic. Solomon Wilcots, our Players’ Council leader, has collaborated with former athletes nationally with the goal of expanding the collection to additional sites across the U.S.”

For more information about the project, details about the upcoming study collection and study coordinator contact information, please visit www.tgen.org/cte.

Separately, Aethlon announced that a patent covering its TAUSOMETM and other CTE biomarker-based intellectual property for detecting brain pathologies has issued in Europe. The European patent specifically covers devices and methods for diagnosing CTE and Alzheimer’s disease using biomarkers such as TAUSOMETM, β-amyloid and others from saliva, urine, blood or plasma.  The patent is effective in Denmark, France, Germany, Ireland, the Netherlands, Sweden, Switzerland, and the UK. Corresponding patent applications are pending in the United States.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy